Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun 14;15(1):227.
doi: 10.1007/s12672-024-01087-w.

Exploring prognostic values of DNA ploidy, stroma-tumor fraction and nucleotyping in stage II colon cancer patients

Yutong Lou #  1 , Lujing Yang #  2 , Shaojun Xu #  1 , Luxin Tan  1 , Yanhua Bai  1 , Lin Wang  3 , Tingting Sun  3 , Lixin Zhou  1 , Li Feng  4 , Shenyi Lian  5 , Aiwen Wu  6 , Zhongwu Li  7   8   9
Affiliations

Exploring prognostic values of DNA ploidy, stroma-tumor fraction and nucleotyping in stage II colon cancer patients

Yutong Lou et al. Discov Oncol. .

Abstract

Purpose: To assess the prognostic value of three novel biomarkers, DNA ploidy, stroma-tumor fraction, and nucleotyping, seeking for more accurate stratification in stage II colon cancer.

Methods: A total of 417 patients with complete follow up information were enrolled in this study and divided into three clinical risk groups. IHC was performed to examine MSI status. DNA ploidy, stroma and nucleotyping were estimated using automated digital imaging system. Kaplan-Meier survival curves, Cox proportional hazards regression models, and correlation analyses were carried out to process our data.

Results: In the whole cohort of stage II colon cancer, nucleotyping and DNA ploidy were significant prognostic factors on OS in univariate analyses. The combination of nucleotyping and DNA ploidy signified superior OS and DFS. Difference was not significant between low-stroma and high-stroma patients. In multivariable analyses, nucleotyping and the combination of nucleotyping and DNA ploidy were proven the dominant contributory factors for OS. In the low-risk group, we found the combination of nucleotyping and DNA ploidy as the independent prognostic factor statistically significant in both univariate and multivariable, while in the high-risk group, the nucleotyping.

Conclusions: Our study has proven nucleotyping and the combination of DNA ploidy and nucleotyping as independent prognostic indicators, thus expanding the application of nucleotyping as a predictor from high risk stage II colon cancer to whole risks.

Keywords: Colon cancer; Nucleotyping; Ploidy; Prognosis; Stroma.

PubMed Disclaimer

Conflict of interest statement

The authors have no competing interests to declare that are relevant to the content of this article.

Figures

Fig. 1
Fig. 1
Kaplan–Meier plots illustrating OS for patients that were classified according to nucleotyping (a) and DNA ploidy (b) in the whole cohort of stage II colon cancer
Fig. 2
Fig. 2
Kaplan–Meier plots illustrating OS for patients that were divided into three subgroups: diploidy and low stroma (D and LS), diploidy and high stroma or non-diploidy and low stroma (D and HS or ND and LS), non-diploidy and high stroma (ND and HS) in the whole cohort of stage II colon cancer
Fig. 3
Fig. 3
Kaplan–Meier plots illustrating OS for patients that were divided into three subgroups: CHO and low stroma (CHO and LS), CHO and high stroma or CHE and low stroma (CHO and HS or CHE and LS), CHE and high stroma (CHE and HS) in the whole cohort of stage II colon cancer
Fig. 4
Fig. 4
Kaplan–Meier plots illustrating OS for patients that were divided into three subgroups: CHO and diploidy (CHO and D), CHO and non-diploidy or CHE and diploidy (CHO and ND or CHE and D), CHE and non-diploidy (CHE and ND) in the whole cohort of stage II colon cancer
See this image and copyright information in PMC

References

    1. Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl) 2021;134(7):783–791. doi: 10.1097/CM9.0000000000001474. - DOI - PMC - PubMed
    1. QUASAR Collaborative Group Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370(9604):2020–2029. doi: 10.1016/S0140-6736(07)61866-2. - DOI - PubMed
    1. Weiss JM, Schumacher J, Allen GO, et al. Adjuvant chemotherapy for stage II right- and left-sided colon cancer: analysis of SEER-medicare data. Ann Surg Oncol. 2014;21(6):1781–1791. doi: 10.1245/s10434-014-3631-8. - DOI - PMC - PubMed
    1. Schmoll HJ. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol. 2012;23(10):2479. doi: 10.1093/annonc/mds236. - DOI - PubMed
    1. Argilés G, Tabernero J, Labianca R, et al. Localised colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-upy. Ann Oncol. 2020;31(10):2479. doi: 10.1016/j.annonc.2020.06.022. - DOI - PubMed

LinkOut - more resources